About 2,218,398 results

Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
Meghan Nelson, Colleen Mosley, D. Sofia Villacis-Nunez et. al.

Nov 14th, 2022 - Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that is associated with significant disease damage, morbidity, and mortality. In comparison to the adult population, childhood onset SLE (cSLE) tends to be more aggressive given the higher preponderance of renal and neuropsychiatric disease and increased disease activity. There is a paucity of literature ...

Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review
Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Pamela Munguía-Realpozo et. al.

Nov 14th, 2022 - Background/Purpose: There is increased interest in machine learning (ML)-based prediction models in systemic lupus erythematosus (SLE). We made a systematic review of adherence in diagnostic and prognostic applications of ML in SLE using the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Statement. Methods: A systematic review using 5 da...

SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
Alfredo Aguirre, Mimi Kim, Kosalaram Goteti et. al.

Nov 14th, 2022 - Background/Purpose: The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) are currently the most common primary endpoints in systemic lupus erythematosus (SLE) randomized-controlled trials (RCTs). However, discordance between SRI-4 and BICLA effect sizes in studies has engendered skepticism about ...

Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Kathryn Connelly, Laura Eades, Rachel Koelmeyer et. al.

Nov 14th, 2022 - Background/Purpose: Most late-phase randomised controlled trials (RCTs) of novel drugs for systemic lupus erythematosus (SLE) have failed to meet their primary endpoint or shown contradictory efficacy results(1). While many factors contribute to RCT failure, how best to measure treatment benefit remains a challenge(1). For product approval, regulators require evidence of clinical benefit, defin...

Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
Sandra Sze-jung Wu, Allison Perry, Nicole Zimmerman et. al.

Nov 14th, 2022 - Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an SLE flare among patients remains a challenge for physicians. To identify risk factors associated with SLE flares requiring an emergency room visit (ER) or inpatient (IP) admission, among Medicaid enr...

Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
Gul Karakoc, Ge Liu, Jorge Gamboa et. al.

Nov 14th, 2022 - Background/Purpose: SLE disproportionately affects individuals of African (AA) compared to European ancestry (EA). In addition to a higher incidence, the disease is more severe in patients of AA; they have a higher burden of renal comorbidities such as end stage renal disease (ESRD) and others (1). A high risk (HR) genotype in apolipoprotein L1 (APOL1), present in 13% of AA and absent in EA ind...

Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry
Chiharu Hidekawa, Ryusuke Yoshimi, Yusuke Saigusa et. al.

Nov 14th, 2022 - Background/Purpose: Infections are significant causes of mortality in patients with systemic lupus erythematosus (SLE), and their prevention is essential. Although some previous reports have shown the efficacy of hydroxychloroquine (HCQ) in preventing infection, there is no such evidence in the Japanese population. Here we investigated the effect of HCQ on reducing infections in SLE patients in...

Trajectories of Disease Activity in a Longitudinal Registry of Pediatric SLE
Siobhan Case, Larry Hill, Anne Dennos et. al.

Nov 14th, 2022 - Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is associated with significant morbidity and multiorgan dysfunction. Single-center studies have described disease activity and damage trajectories for pSLE, which varied by self-reported ethnicity and did not include measures of socioeconomic status. We utilized data from the Childhood Arthritis and Rheumatology Research Alliance...

Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
Dafna Gladman, KONSTANTINOS TSELIOS, Jiandong Su3 and Murray Urowitz et. al.

Nov 14th, 2022 - Background/Purpose: Lupus nephritis (LN) affects up to 40% of patients with SLE and leads to end stage kidney disease (ESKD) in 17-33% after 10 years. The prevalence of chronic kidney disease stage IV (estimated glomerular filtration rate, eGFR=15-29ml/min/1.73m2) is not known; however, approximately two thirds of such patients will progress to ESKD after 6 years on average.1 Objective: To dete...

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
J. Patricia Dhar, Forsythe Hannah, Louis Saravolatz3 and Susanna Szpunar et. al.

Nov 14th, 2022 - Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to be immunocompromised & thus fall into the Advisory Committee on Immunization Practice’s (ACIP) immunosuppressed category. Vaccines for influenza, pneumococcus, pertussis, varicella, & HPV are safe ...

Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
Astrid Rasmussen, R. Hal Scofield, Kiely Grundahl et. al.

Nov 14th, 2022 - Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in SLE and multiple sclerosis have shown that Met associates with reduced Th17 cells, IL-17, IL-1b, IL-6, IFN-g, and TNF-a, while restoring or increasing regulatory T-cells (Treg). Sjögren’s D...

Sjögren’s Disease and Mitochondrial Function
Biji T Kurien, Pharaoh Gavin, Joshua Cavett et. al.

Nov 14th, 2022 - Background/Purpose: Sjögren’s disease (SjD) is a chronic inflammatory, autoimmune disorder with reduced lacrimal/salivary gland secretion resulting in keratoconjunctivitis sicca and xerostomia, respectively. Also, SjD patients have increased rates of metabolic syndrome and experience significant fatigue. Metabolic syndrome and fatigue are associated with chronic low-level inflammation. Our prev...

Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
Maxime Beydon, Marie Dulin, Raphaèle Seror et. al.

Nov 14th, 2022 - Background/Purpose: It is well established that in systemic lupus erythematous (SLE), disease burden is higher in patients from African ancestry (AA) than in Caucasian patients. Although primary Sjögren’s syndrome (pSS) and SLE vary by their clinical presentation, they share common pathogenic mechanisms. Our objectives were to compare demographic and biological parameters as well as disease act...

Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome
Shruti Singh Kakan, Yaping Ju, Maria Edman2 and Sarah Hamm-Alvarez et. al.

Nov 14th, 2022 - Background/Purpose: Sjögren’s Syndrome (SS) is an autoimmune disease characterized by infiltration of lymphocytes into lacrimal (LG) and salivary (SG) glands and their concurrent loss of tear and saliva production, respectively, as well as the development of systemic symptoms. Diagnosis of SS takes ~3 years, due in part to manifestation of symptoms that overlap with other autoimmune diseases. R...

Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
Gregoire Martin de Fremont, Nathalie Costedoat-Chalumeau, Rakiba Belkhir et. al.

Nov 14th, 2022 - Background/Purpose: In the context of primary Sjögren’s syndrome (pSS), only a few retrospective studies using heterogeneous methods have investigated the risk of adverse pregnancy outcomes (APO) with inconsistent results (APO frequency ranging from similar to the general population to ≥50% of pregnancies). Moreover, these studies rarely analyzed the impact of pregnancy on the course of pSS. We...

Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
Maxwell Parker, Zihao Zheng, Quinn Parker et. al.

Nov 14th, 2022 - Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients who are anti-SSA antibody negative (SSA-), a salivary gland biopsy is required for diagnosis. Our objective was to identify novel autoantibodies as a non-invasive means to diagnose SSA- SjD. Methods: Using sera from S...

Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease
Anna Nagel, Bhuwan Khatri, Marcin Radziszewski et. al.

Nov 14th, 2022 - Background/Purpose: Dysregulated autophagy is implicated in systemic lupus erythematous (SLE) and Sjögren’s disease (SjD), including dysregulated expression of Autophagy-related gene 5 (ATG5) and Autophagy Related 16 Like 2 (ATG16L2) [1-3]. ATG16L2–P2RY2 and PRDM1–ATG5 loci are genome-wide significant (GWS) association in SLE [3,4]. This study aims to identify autophagy-related SLE and SjD ris...

Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
Jesus Diaz, Guillermo Quiceno2 and Adela Castro, Hamilton Medical Center et. al.

Nov 14th, 2022 - Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly comparing their clinical efficacy (1)(2). In such situations, network meta-analysis (NMA) can be useful. This study aims to compare the efficacy of biologics and targeted synthetic therapies for patients w...

Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-...
Jessica Walsh, Laura Coates, Philip J Mease et. al.

Nov 14th, 2022 - Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using data from BE OPTIMAL and BE COMPLETE. Methods: BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) were phase 3 studies of bimekizumab (BKZ) in patients with active PsA who were bDMARD-naï...

Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Laure Gossec, Mohamed Sharaf, Elke Theander et. al.

Nov 14th, 2022 - Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic arthritis (PsA) who had inadequate response (IR; insufficient efficacy or intolerance) to 1–2 tumor necrosis factor inhibitors (TNFi).1 The purpose of this analysis is to assess the efficacy of GUS 100 mg Q8W in TN...